---
product_id: 556994053
title: "– The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs (The Maudsley Prescribing Guidelines Series)"
price: "€ 119.53"
currency: EUR
in_stock: true
reviews_count: 13
url: https://www.desertcart.hr/products/556994053-the-maudsley-deprescribing-guidelines-antidepressants-benzodiazepines-gabapentinoids-and-z-drugs
store_origin: HR
region: Croatia
---

# WHO-backed patient rights & clinical research 592 pages of evidence-based guidance Step-by-step tailored tapering schedules – The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs (The Maudsley Prescribing Guidelines Series)

**Price:** € 119.53
**Availability:** ✅ In Stock

## Summary

> 📚 Unlock the future of psychiatric care with the ultimate deprescribing playbook!

## Quick Answers

- **What is this?** – The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs (The Maudsley Prescribing Guidelines Series)
- **How much does it cost?** € 119.53 with free shipping
- **Is it available?** Yes, in stock and ready to ship
- **Where can I buy it?** [www.desertcart.hr](https://www.desertcart.hr/products/556994053-the-maudsley-deprescribing-guidelines-antidepressants-benzodiazepines-gabapentinoids-and-z-drugs)

## Best For

- Customers looking for quality international products

## Why This Product

- Free international shipping included
- Worldwide delivery with tracking
- 15-day hassle-free returns

## Key Features

- • **Precision Tapering Mastery:** Customizable, drug-specific tapering regimens to minimize withdrawal discomfort and optimize patient outcomes.
- • **Clear Symptom Differentiation:** Expert strategies to distinguish withdrawal symptoms from relapse, empowering confident clinical decisions.
- • **Empowering Clinicians & Patients:** Bridges the knowledge gap with accessible guidance for psychiatrists, GPs, pharmacists, and informed patients alike.
- • **Comprehensive Multi-Drug Coverage:** Covers antidepressants, benzodiazepines, gabapentinoids, and z-drugs with practical troubleshooting insights.
- • **Clinically Authoritative & Current:** Grounded in the latest research and WHO/UN recommendations, setting the gold standard for deprescribing psychiatric meds.

## Overview

The Maudsley Deprescribing Guidelines is a 592-page, evidence-based clinical resource published in 2024, offering step-by-step, drug-specific tapering protocols for safely reducing or stopping antidepressants, benzodiazepines, gabapentinoids, and z-drugs. Backed by WHO and UN patient rights frameworks, it uniquely clarifies withdrawal versus relapse symptoms and provides practical troubleshooting, making it an essential, authoritative guide for healthcare professionals and patients committed to safe, informed deprescribing.

## Description

The Maudsley® Deprescribing Guidelines Comprehensive resource describing guidelines for safely reducing or stopping (deprescribing) antidepressants, benzodiazepines, gabapentinoids and z-drugs for patients, including step-by-step guidance for all commonly used medications, covering common pitfalls, troubleshooting, supportive strategies, and more. Most formal guidance on psychiatric medication relates to starting or switching medications with minimal guidance on deprescribing medication. In 2023, the World Health Organisation and the United Nations called for patients, as a human right, to be informed of their right to discontinue treatment and to receive support to do so. The Maudsley Deprescribing Guidelines fills a significant gap in guidance for clinicians by providing comprehensive and authoritative information on this important aspect of treatment. This evidence-based handbook provides an overview of principles to be used in deprescribing. This is derived from fundamental scientific principles and the latest research on this topic, combined with emerging insights from clinical practice (including from patient experts). Building on the recognised brand of The Maudsley Prescribing Guidelines , and the prominence of the authors’ work, including in The Lancet Psychiatry on tapering antidepressants (the most read article across all Lancet titles when it was released). The Maudsley Deprescribing Guidelines covers topics such as: Why and when to deprescribe antidepressants, benzodiazepines, gabapentinoids and z-drugs Barriers and enablers to deprescribing including physical dependence, social circumstances, and knowledge about the discontinuation process Distinguishing withdrawal symptoms, such as poor mood, anxiety, insomnia, and a variety of physical symptoms from symptoms of the underlying disorder that medication was intended to treat The difference between physical dependence and addiction/substance use disorder Explanation of why and how to implement hyperbolic tapering in clinical practice Specific guidance on formulations of medication and techniques for making gradual reductions, including using liquid forms of medication, and other approaches Step-by-step guidance for safely stopping all commonly used antidepressants, benzodiazepines, gabapentinoids and z-drugs, including fast, moderate and slow tapering regimens or schedules for each drug, and guidance on how to tailor these to an individual Troubleshooting issues which can arise on stopping these medications, including akathisia, withdrawal symptoms, acute or protracted, and relapse. Written for anyone interested in safe deprescribing of psychiatric medications including psychiatrists, GPs, pharmacists, nurses, medical trainees, and interested members of the public. The Maudsley Deprescribing Guidelines is an essential resource on the subject that provides practical guidance on how to improve patient outcomes in this field of medicine.

Review: Things you should know about - If you are taking certain prescribed medications and you have decided to come off of them for whatever reason, and you want to minimise possible discomfort, this is a great tool for safe guidance to achieve your goal. Unfortunately, many healthcare providers can prescribe certain medications, but in my opinion, they have no real idea how to get you off of them. The guidelines provided to them are often outdated and can cause unnecessary discomfort; however, those guidelines are gradually being reviewed and amended to align with those included in this amazing book. If you want to educate yourself and your prescriber, this is exactly what you need.
Review: Essential advice - The book is well founded and evidence based. It gives clear guidelines in unusual prescribing scenarios. For example: Some prescribers can be scared of using preparations like diazepam liquid in very low doses, out of fear that this is not licensed. In the absence of official guidelines this book can be used as reassurance to do the right thing. Most of the advice is common sense. Some sections, such as the one about deprescribing benzodiazepines, can be a bit repetitive, but this does not affect my 5 star review.

## Features

- Step-by-step guidance for safely reducing or stopping psychiatric medications, including tapering schedules tailored to individual needs
- Clear distinction between withdrawal symptoms and relapse, with strategies to support patients through the deprescribing process
- Authoritative resource backed by clinical research and WHO/UN recommendations on patients’ rights to discontinue treatment

## Technical Specifications

| Specification | Value |
|---------------|-------|
| Best Sellers Rank | 70,089 in Books ( See Top 100 in Books ) 614 in General Medical Issues Guides 644 in Other Branches of Medicine 881 in Scientific Psychology & Psychiatry |
| Customer reviews | 4.7 4.7 out of 5 stars (236) |
| Dimensions  | 16.76 x 3.05 x 24.13 cm |
| Edition  | 1st |
| ISBN-10  | 111982298X |
| ISBN-13  | 978-1119822981 |
| Item weight  | 1.1 kg |
| Language  | English |
| Part of series  | The Maudsley Prescribing Guidelines |
| Print length  | 592 pages |
| Publication date  | 15 Feb. 2024 |
| Publisher  | Wiley-Blackwell |

## Images

![– The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs (The Maudsley Prescribing Guidelines Series) - Image 1](https://m.media-amazon.com/images/I/71qG59VbNcL.jpg)

## Customer Reviews

### ⭐⭐⭐⭐⭐ Things you should know about
*by N***B on 22 February 2026*

If you are taking certain prescribed medications and you have decided to come off of them for whatever reason, and you want to minimise possible discomfort, this is a great tool for safe guidance to achieve your goal. Unfortunately, many healthcare providers can prescribe certain medications, but in my opinion, they have no real idea how to get you off of them. The guidelines provided to them are often outdated and can cause unnecessary discomfort; however, those guidelines are gradually being reviewed and amended to align with those included in this amazing book. If you want to educate yourself and your prescriber, this is exactly what you need.

### ⭐⭐⭐⭐⭐ Essential advice
*by S***G on 20 March 2026*

The book is well founded and evidence based. It gives clear guidelines in unusual prescribing scenarios. For example: Some prescribers can be scared of using preparations like diazepam liquid in very low doses, out of fear that this is not licensed. In the absence of official guidelines this book can be used as reassurance to do the right thing. Most of the advice is common sense. Some sections, such as the one about deprescribing benzodiazepines, can be a bit repetitive, but this does not affect my 5 star review.

### ⭐⭐⭐⭐⭐ A brave and essential publication
*by A***R on 24 January 2024*

The authors are to be highly commended for compiling such an important collation of the information 'to date' (November 2023) on the complex issue of the deprescribing - of antidepressants, benzos, gabapentinoids and z-drugs. Having contributed to the patient experience gathered within the reference material cited, it is heartening to see this now being used constructively to inform prescribers - with the express purpose of limiting the damage that we have seen far too many people experiencing - whilst the medical profession has been slow to recognise what has been happening to real life patients. This book will surely raise awareness and kick-start long overdue proper recognition and further exploration of the issues raised - especially in the preliminary discussion section. The future 'proof of the pudding' around the specific drug guidance will itself yield essential information and better understanding of 'what works' in real life for real patients. And then there is the problem of polypharmacy: all too often antidepressants are now the 'gateway' drugs, leading on to the other drugs covered within the book.

## Frequently Bought Together

- The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs (The Maudsley Prescribing Guidelines Series)
- The Maudsley Prescribing Guidelines in Psychiatry (The Maudsley Prescribing Guidelines Series)
- The Maudsley Practice Guidelines for Physical Health Conditions in Psychiatry (The Maudsley Prescribing Guidelines Series)

---

## Why Shop on Desertcart?

- 🛒 **Trusted by 1.3+ Million Shoppers** — Serving international shoppers since 2016
- 🌍 **Shop Globally** — Access 737+ million products across 21 categories
- 💰 **No Hidden Fees** — All customs, duties, and taxes included in the price
- 🔄 **15-Day Free Returns** — Hassle-free returns (30 days for PRO members)
- 🔒 **Secure Payments** — Trusted payment options with buyer protection
- ⭐ **TrustPilot Rated 4.5/5** — Based on 8,000+ happy customer reviews

**Shop now:** [https://www.desertcart.hr/products/556994053-the-maudsley-deprescribing-guidelines-antidepressants-benzodiazepines-gabapentinoids-and-z-drugs](https://www.desertcart.hr/products/556994053-the-maudsley-deprescribing-guidelines-antidepressants-benzodiazepines-gabapentinoids-and-z-drugs)

---

*Product available on Desertcart Croatia*
*Store origin: HR*
*Last updated: 2026-08-11*